Alzinova AB · OMXSTO:ALZ

Alzinova AB — Investor Presentation (October 2023)

33 slides from Alzinova AB's investor presentation, Oct 13, 2023

  1. Slide 1: Alzinova Company presentation October 2023

    We will make it possible for Alzheimer's patients Alzinova to live an independent and active life Company presentation | October | 2023 ©2023 Alzinova AB (publ), All rights reserved

  2. Slide 2: Forward looking statements

    Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate

  3. Slide 3: Imagine if there was a vaccine against Alzheimer's disease

    Imagine if there was a vaccine against Alzheimer's disease ©2023 Alzinova AB (publ), All rights reserved

  4. Slide 4: Alzinova is developing the first specific vaccine against Alzheimer's disease

    Swedish biopharma company | Based in Gothenburg Founded 2011 Alzinova is High unmet medical need for Alzheimer’s disease developing the – huge market opportunity first specific Innovative science & proprietary technology enables development of vaccine against disease-modifying treatments for Alzheim

  5. Slide 5: Alzheimer's disease

    Alzheimer’s disease • Slowly progressing disease • Caused by toxic formations in the brain called oligomers – consists of Aβ-42 peptide • Destroys brain structures Memory Delusions Loss of loss, & poor Depression Agitation independent Cause of confusion judgement life death • Need for targeted treat

  6. Slide 6: Alzheimer's disease – huge unmet medical need

    Alzheimer’s disease – huge unmet medical need Dementia >55 million people suffer from dementia Impacts >150 million people in 2050 quality of life US $1.3 trillion (US $2.8 trillion by 2030) Patients, families, Annual cost care givers 60-70% are Alzheimer’s patients World Alzheimer’s Report 2015, 20

  7. Slide 7: >100 million people will suffer from Alzheimer's in 2050

    >100 million people will suffer from Alzheimer’s in 2050 ©2023 Alzinova AB (publ), All rights reserved

  8. Slide 8: Enormous market potential

    Enormous market potential Alzheimer’s therapeutics market > US $13 billion by 2028 Substantial market 2 out of 7 predicted blockbusters by 2026 are new anti-Alzheimer’s drugs with US $1.7 - 4.5 billion projected annual revenue potential for Alzinova Market growth driven by introduction of novel ther

  9. Slide 9: Potential breakthrough in Alzheimer's

    Potential breakthrough in Alzheimer’s ✓ ✓ ✓ High unmet medical & market potential for disease-modifying treatments of Alzheimer’s disease Short-term goal: Mid-term goal: Long-term goal:  First clinical trial targeting  ALZ-101 Enter Phase 2 in  Bring to market in oligomers with a therapeutic 2024

  10. Slide 10: Alzinova's business model – develop, document, prepare, partner & bring to market

    Develop breakthrough disease-modifying treatments based on proprietary AβCC technology Document safety and tolerability in patients with Alzheimer’s disease Alzinova’s business model – develop, document, Prepare (in parallel) for phase 2 to optimize the candidates value prepare, partner & bring to m

  11. Slide 11: Our candidates for treating Alzheimer's disease

    Our candidates for treating Alzheimer’s disease ©2023 Alzinova AB (publ), All rights reserved

  12. Slide 12: AβCC peptide technology enables high precision targeting of toxic oligomers

    Alzinova’s AβCC peptide™ technology enables high precision, with antibodies specifically targeting the toxic oligomers Aβ – amyloid-beta ©2023 Alzinova AB (publ), All rights reserved

  13. Slide 13: Two differentiated, oligomer-specific products based on the same proprietary technology

    Two differentiated, oligomer- specific products based on the same proprietary technology • Highly specific disease modifying treatments, directed towards the toxic accumulations of amyloid beta in the brain • Opportunity to become effective and well tolerated treatments to halt and prevent Alzheimer

  14. Slide 14: ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease

    ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease • The body generates specific antibodies against toxic oligomers ALZ-101 vaccine • High patient compliance (few booster doses) • Long-acting • Preventive treatment possible • Large potential patient population ©2023 Alzinova

  15. Slide 15: ALZ-201 a complement to the vaccine ALZ-101

    ALZ-201 a complement to the vaccine ALZ-101 in treating Alzheimer's Disease • Unique binding profile for targeting toxic oligomers ALZ-201 monoclonal antibody • Several potential uses for the antibody: − complement to the vaccine ALZ-101 for patients who, for various reasons, need higher levels of a

  16. Slide 16: Improving quality of care – for more patients

    Improving quality of care – for more patients Based on Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost. ©2023 Alzinova AB (publ), All rights reserved Sources: SCB Statistics Sweden, Swedish regional healthcare cost

  17. Slide 17: Alzinova's product pipeline

    Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Major Milestone ALZ-1011) therapeutic Positive interim Q4 2023, Topline data clinical phase 1b vaccine data May 2023 ALZ-2012) monoclonal antibody TBD “Phase 1 r

  18. Slide 18: What if there was a vaccine for Alzheimer's?

    What if there was a vaccine for Alzheimer's? Alzinova Other actors Targeted treatment – oligomer specific Target plaques ​ Vaccine Non-specific treatments Antibody - as a complement to the vaccine Often complicated drug treatments Fast, effective and uncomplicated Unlikely to be sufficiently effecti

  19. Slide 19: ALZ-101 – favorable profile with best-in-class opportunity

    ALZ-101 – favorable profile with “best-in-class” opportunity ALZ-101 Donanemab Lecanemab Companies Alzinova Eli Lilly BioArctic/Eisai/Biogen Primary target Aβ oligomers plaque (P-Glu3-Aβ) Aβ monomers/fibrils/oligomers –> good efficacy +++ (potential) + + Compliance +++ + + Low cost* +++ ++ + Low soc

  20. Slide 20: ALZ-101 & ALZ-201 are patented through two patent families

    ALZ-101 & ALZ-201 are patented through two patent families Stable amyloid-beta monomers and oligomers (ALZ-101) Region/Country Patent number Status Expiry date Australia 2009236699 Granted 2029-04-14 Europe(1) 2262526 Granted 2029-04-14 Japan 5817060 Granted 2029-04-14 We maintain an Japan 6128450 G

  21. Slide 21: Strong data supports clinical development of ALZ-101

    Strong data supports clinical development of ALZ-101 Comprehensive pre-clinical results  Efficacy data in three different Alzheimer’s models - with promising results Robust and validated process for manufacturing of drug substance and product  GMP manufacturing of vaccine – Phase 1b  Scale up man

  22. Slide 22: Alzinova's ALZ-101 Phase 1b-study

    Alzinova’s ALZ-101 Phase 1b-study ©2023 Alzinova AB (publ), All rights reserved

  23. Slide 23: ALZ-101 Phase 1b clinical study in patients with Alzheimer's disease

    ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease Study: Double-blind, randomized, placebo-controlled study on safety, tolerability and immunogenicity. 20-week study with ALZ-101 (125 and 250 μg) or placebo, given at weeks 0, 4, 8 and 16 with a follow-up period of 48 weeks. Patien

  24. Slide 24: Strong interim data in Phase 1b Study

    Strong interim data in Phase 1b Study Interim analysis - good safety and tolerability with a clear immune response - 26 subjects included - treated with at least 3 doses of ALZ-101 (125 and 250 μg) or placebo - increasing antibody levels with number of doses given Extension of phase 1b study - All p

  25. Slide 25: Phase 2 preparations

    Phase 2 preparations Interactions with Regulatory Authorities – FDA and EMA Comprehensive preparation work - Scalable manufacturing process - Study design and protocol development - CRO and site selection - Fast track application based on Phase 1b data - Intellectual property strategy work - Manufac

  26. Slide 26: Corporate & Finance

    Corporate & Finance ©2023 Alzinova AB (publ), All rights reserved

  27. Slide 27: Experienced management team

    Experienced management team Kristina Torfgård, PhD Anders Sandberg, PhD Håkan Skogström Chief Executive Officer Chief Scientific Officer Chief Financial Officer 30 years experience from leading roles Co-Founder >25 years experience from leading in pharma and biopharma industry >20 years experience i

  28. Slide 28: Board of Directors with extensive pharma and biopharma experience

    Julian Aleksov Anders Blom Per-Göran Gillberg, PhD Clas Malmeström, MD, PhD Chairman Member Member Member >25 years experience in finance and >25 years experience in international 35 years experience in drug development Chief physician MS-center, neuro- international development within finance and b

  29. Slide 29: Capitalization table, summary of shares and options

    Capitalization table, summary of shares and options Shareholders, as per 29 September 2023: Name No. of shares Capital, % Maida Vale Capital AB 6,747,686 15.15% Försäkrings AB Avanza Pension 3,223,681 7.24% Nordnet Pensionsförsäkring AB 2,229,751 5.01% Patrik Ahlvin 1,004,750 2.26% Sara Gjertz 877,3

  30. Slide 30: Financial information – Key figures, Jan-Jun 2023

    Financial information Key figures, for Jan-Jun 2023 (Jan-Jun 2022) Total balance sheet Cash balance Cashflow Result Equity ratio 127 37 3,2 -8.2 96% (117) (44) (-27,1) (-5.6) (96%) MSEK MSEK MSEK MSEK • Mainly invested in capitalized costs for R&D, focus on present ALZ-101 phase 1 study and preparin

  31. Slide 31: Roadmap & value inflection points

    Roadmap & value inflection points Phase 1b study interim data ALZ-101 Phase 1b study results ALZ-101 Phase 2 Study 2023 Q2 2023 Q4 2024+ 2023 Q2 2023+ 2024+ Phase 1b study extension Fast track application ALZ-101 ALZ-201 Phase 1b Study Cash to finance ALZ-101 through phase 1b and preparatory ahead o

  32. Slide 32: Investment highlights

    Investment highlights Alzinova’s goal is to enable Alzheimer’s patients to live an independent and active life. Alzinova’s lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer’s in clinical development with a phase 1b study in patients. Based on the same technology, Alzinova is also d

  33. Slide 33: Alzinova

    CEO Kristina Torfgård Alzinova Email: kristina.torfgard@alzinova.com Phone: +46 70 846 79 75 www.alzinova.com https://www.linkedin.com/company/alzinova-ab/ ©2023 Alzinova AB (publ), All rights reserved

Alzinova — Investor Presentation (October 2023) on 6ix